We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) yesterday and set a ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.

The study investigates COVID-19 vaccine-related myocarditis in adolescents, revealing clinical characteristics and risks of ...